metformin has been researched along with Active Hyperemia in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin." | 9.16 | Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. ( Bank, AJ; Bergenstal, RM; Gonzalez-Campoy, JM; Katz, H; Kelly, AS, 2012) |
| "I/R and its subsequent reactive hyperemia results in different adverse effects such as brain edema and BBB disruption." | 5.42 | Targeting Adenosine Monophosphate-Activated Protein Kinase by Metformin Adjusts Post-Ischemic Hyperemia and Extracellular Neuronal Discharge in Transient Global Cerebral Ischemia. ( Ashabi, G; Badavi, M; Farbood, Y; Khalaj, L; Khodagholi, F; Sarkaki, A, 2015) |
| "0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin." | 5.16 | Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. ( Bank, AJ; Bergenstal, RM; Gonzalez-Campoy, JM; Katz, H; Kelly, AS, 2012) |
| "I/R and its subsequent reactive hyperemia results in different adverse effects such as brain edema and BBB disruption." | 1.42 | Targeting Adenosine Monophosphate-Activated Protein Kinase by Metformin Adjusts Post-Ischemic Hyperemia and Extracellular Neuronal Discharge in Transient Global Cerebral Ischemia. ( Ashabi, G; Badavi, M; Farbood, Y; Khalaj, L; Khodagholi, F; Sarkaki, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farbood, Y | 1 |
| Sarkaki, A | 1 |
| Khalaj, L | 1 |
| Khodagholi, F | 1 |
| Badavi, M | 1 |
| Ashabi, G | 1 |
| Kelly, AS | 1 |
| Bergenstal, RM | 1 |
| Gonzalez-Campoy, JM | 1 |
| Katz, H | 1 |
| Bank, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance[NCT00546728] | Phase 4 | 50 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in reactive hyperemic index over the 3-month treatment period, which is a measure of endothelial (inner lining of blood vessels) function. This is measured as a ratio of post-occlusion blood flow volume versus baseline blood flow volume in fingertips. Higher ratio values are considered indicative of better arterial health. (NCT00546728)
Timeframe: Change from baseline to 3 months
| Intervention | ratio (Mean) |
|---|---|
| Exenatide | 0.01 |
| Metformin | -0.17 |
1 trial available for metformin and Active Hyperemia
| Article | Year |
|---|---|
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Endothelium, Vascular; Ex | 2012 |
1 other study available for metformin and Active Hyperemia
| Article | Year |
|---|---|
Targeting Adenosine Monophosphate-Activated Protein Kinase by Metformin Adjusts Post-Ischemic Hyperemia and Extracellular Neuronal Discharge in Transient Global Cerebral Ischemia.
Topics: AMP-Activated Protein Kinases; Animals; Blood-Brain Barrier; Brain Ischemia; Hyperemia; Male; Metfor | 2015 |